Quick Answer
NewAmsterdam Pharma Co N.V. reported Stockholders Equity of $683.43 million for the year ending 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -9.8% in Stockholders Equity from 2024 to 2025.
- This data is from NewAmsterdam Pharma Co N.V.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $398.41 million | Q2 2023: $373.34 million | Q3 2023: $331.84 million | Q1 2024: $411.80 million | Q2 2024: $387.44 million | Q3 2024: $378.86 million | Q1 2025: $777.36 million | Q2 2025: $778.50 million | Q3 2025: $728.07 million.
- Over the full 6 years of available data (2020 to 2025), NewAmsterdam Pharma Co N.V.'s Stockholders Equity has grown by 1,035.8%.
- Historical annual values: Fiscal year 2025: $683.43 million | Fiscal year 2024: $757.50 million | Fiscal year 2023: $288.39 million | Fiscal year 2022: $430.07 million | Fiscal year 2021: -$113.82 million | Fiscal year 2020: -$73.04 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: